Biogen leads the amyotrophic lateral sclerosis hopefuls

Amylyx’s decision this week to pursue early US approval of its amyotrophic lateral sclerosis project, AMX0035, put the focus back on a field that has seen more than its fair share of disappointment of late.

And surprisingly, the mid-to-late-stage pipeline is looking full, with many different approaches being tested. “I’ve been in the field for about nine years and, during that time, there’s never been as many trials and companies as there are today,” Amylyx’s co-chief executive officer, Josh Cohen, told Evaluate Vantage.

However, he added a note of caution: “I think it’s going to take a lot of shots on goal. We can’t expect every trial to succeed.”